Genocea Biosciences (GNCA) Stock Price, News & Analysis

Company Overview

Genocea Biosciences, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel T cell-directed therapies and vaccines for oncology and infectious diseases. Headquartered in Cambridge, Massachusetts, Genocea aims to leverage the body’s natural immune response by identifying the precise antigens that drive protective T cell activity.

The company’s proprietary ATLAS platform enables comprehensive mapping of antigen-specific CD4+ and CD8+ T cell responses. By screening patient-derived samples against a broad library of peptides, ATLAS identifies the targets most likely to elicit potent, disease-relevant immune responses. Genocea is applying this technology across multiple programs, including investigational cancer vaccines and infectious disease initiatives, and is pursuing strategic collaborations with pharmaceutical and biotechnology partners to advance its pipeline.

Founded in 2011 as a spin-out from academic research, Genocea has built a multidisciplinary team of immunologists, molecular biologists and clinical development experts. While the company’s early work established proof of concept for its epitope identification approach, ongoing efforts are focused on translating ATLAS discoveries into off-the-shelf and personalized immunotherapies. Genocea serves a global market through its Cambridge laboratories and collaborative network, with the goal of accelerating next-generation treatments that harness T cell immunity.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,300 shs
• Average Volume: 83,499 shs
• Market Capitalization: $6 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNCA Stock Analysis - Frequently Asked Questions

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter.

How do I buy shares of Genocea Biosciences?

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW) and Micron Technology (MU).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNCA
• CIK: 1457612
• Web: www.genocea.com
• Phone: (617) 876-8191
• Fax: 617-876-8192
• Employees: 70
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($0.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.20 million
• Net Margins: N/A
• Pretax Margin: -1,946.15%
• Return on Equity: -182.88%
• Return on Assets: -62.76%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 1.35
• Quick Ratio: 1.35

Sales & Book Value

• Annual Sales: $1.91 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.47 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,730,000
• Free Float: 57,788,000
• Market Cap: $6 thousand
• Optionable: Not Optionable
• Beta: 1.61